Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his 'Liberation Day' ...

FTSE 100 p harma giants GSK and Astrazeneca may have escaped the worst of US President Donald Trump’s tariffs, according to a ...

Pharma stocks rise as Trump exempts pharmaceuticals from reciprocal tariffs. Indian, UK, and Japanese drugmakers gain.

Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for ...

Shares of surprise tariff avoiders like pharmaceuticals and drinks firms and rate-sensitive stocks such as real estate were ...

Four years after talks began, a report delivered to Minister for Equality Norma Foley suggests the end point is rather like ...

Vaccine stocks have been under significant pressure in recent days following news that the FDA director who oversaw the ...

NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies ...

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

GSK PLC closed 21.39% short of its 52-week high of £18.24, which the company reached on May 16th.

Find insight on Fisher & Paykel Healthcare, Hims & Hers, GSK and more in the latest Market Talks covering health care.